SCHEMBL4465646

SCHEMBL4465646

COc1cc2nccc(Oc3ccc(NC(=O)NC4CCCC(C)(C)C4)cc3Cl)c2cc1OC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRA P16234 13/20 0.61
KIT P10721 4/20 0.61
KDR P35968 12/20 0.59
MET P08581 4/20 0.55
AXL P30530 3/20 0.53
MERTK Q12866 1/20 0.53
HDAC1 Q13547 1/20 0.51
AURKB Q96GD4 2/20 0.48
FLT3 P36888 1/20 0.48
RIPK2 O43353 1/20 0.48
ERN1 O75460 1/20 0.48
STK10 O94804 1/20 0.48
MAP3K6 O95382 1/20 0.48
ABL1 P00519 1/20 0.48
ESR1 P03372 1/20 0.48
RET P07949 1/20 0.48
PDGFRB P09619 1/20 0.48
ADORA3 P0DMS8 1/20 0.48
BCR P11274 1/20 0.48
FGFR1 P11362 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6234370 0.99 PDGFRA (0.61) PDGFRAKITKDRMETAXL
SCHEMBL4475674 0.90 PDGFRA (0.62) PDGFRAKITKDRMETAXL
SCHEMBL4470899 0.88 PDGFRA (0.79) PDGFRAKITKDRMETHDAC1
SCHEMBL5091893 0.87 PDGFRA (0.59) PDGFRAKITKDRMETAXL
SCHEMBL13936992 0.86 PDGFRA (0.56) PDGFRAKITKDRMETAXL
SCHEMBL4476901 0.85 FGFR4 (0.67) PDGFRAKITKDRMETAXL
SCHEMBL4476077 0.82 MET (0.62) PDGFRAKITKDRMETAXL
SCHEMBL4475372 0.80 KDR (0.67) PDGFRAKITKDRMETAXL
SCHEMBL5824580 0.79 MET (0.57) PDGFRAKITKDRMET
SCHEMBL5088398 0.77 PDGFRA (0.62) PDGFRAKITKDRMETAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20080207617-A1 Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same KIRIN BEER KABUSHIKI KAISHA (JP) 2008-08-28 US disclosed
US-20080207617-A1 Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same KIRIN BEER KABUSHIKI KAISHA (JP) 2008-08-28 US disclosed
EP-1566379-A1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2005-08-24 EP disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 PDGFRA 372/4885KIT 1337/4885KDR 211/4885
US-20080207617-A1 Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same FLT3, TYRO3, ABL1 PDGFRA 229/4885KIT 171/4885KDR 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.